Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients
Open Access
- 28 February 2023
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (4) , 573-586
Abstract
Background The pharmacokinetic variability of ampicillin-sulbactam in adults has not been extensively described, particularly in patients with a reduced renal function (i.e., < 60 mL/min). Objective This study investigated the population pharmacokinetics of ampicillin and sulbactam in patients with a wide range of renal functions and sought to define dosing approaches that have a high likelihood for optimising drug exposure. Methods Serial blood samples were collected from 16 adult patients receiving intravenous ampicillin-sulbactam in general wards. Total ampicillin and sulbactam concentrations were measured by chromatographic assay and pharmacokinetic parameters were estimated using Pmetrics®. Monte Carlo simulations were used to evaluate the probability of target attainment (PTA) of free ampicillin and sulbactam concentrations exceeding the minimum inhibitory concentration (MIC) for 60% and 100% of the dosing interval. Fractional target attainment (FTA) was calculated against MIC distributions of common hospital pathogens. A threshold of ≥ 90% and ≥ 95% was used to define both optimal PTA and FTA, respectively. Results The median (range) age, weight, and serum creatinine of the study population was 68 (40–82) years, 62 (40–82) kg, and 1.4 (0.6–6.4) mg/dL, respectively. The pharmacokinetics of ampicillin and sulbactam were best described by a two-compartment model with serum creatinine most closely associated with clearance for both drugs. The estimated ampicillin and sulbactam clearances were 5.58 L/h and 4.79 L/h, respectively, while the volumes of distribution were 12.6 L and 15.36 L, respectively. Approved dosing regimens of ampicillin-sulbactam were sufficient against MICs ≤ 8 and ≤ 4 mg/L, respectively. A 4-h infusion enabled optimal PTA at higher MICs. For both dosing targets, optimal FTAs were obtained against Streptococcus pneumoniae. Conclusion Optimal FTAs were obtained against the susceptible MIC distributions of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii. Applying a 4-h infusion will enhance PTA and FTA, particularly at higher MICs.Keywords
Funding Information
- Australian National Health and Medical Research Council for a Centre of Research Excellence (APP1099452)
- The University of Queensland
This publication has 38 references indexed in Scilit:
- Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic TargetAntimicrobial Agents and Chemotherapy, 2012
- GFR Estimating Equations in a Multiethnic Asian PopulationAmerican Journal of Kidney Diseases, 2011
- The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill PatientsClinical Pharmacokinetics, 2011
- Where are cut-off values of serum creatinine in the setting of chronic kidney disease?Kidney International, 2010
- Ampicillin/Sulbactam and Cefoxitin in the Treatment of Cutaneous and Other Soft-Tissue Abscesses in Patients With or Without Histories of Injection Drug AbuseClinical Infectious Diseases, 2000
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysisAntimicrobial Agents and Chemotherapy, 1989
- Pharmacokinetics of Sulbactam/Ampicillin in Humans: A ReviewClinical Infectious Diseases, 1986
- Microbiological Studies on a New Broad-spectrum Penicillin, "Penbritin"BMJ, 1961